SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 31.80-0.1%Nov 21 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: aknahow who wrote (4946)11/29/1997 11:21:00 PM
From: Cacaito  Read Replies (2) of 17367
 
George, I have the printed version is a very neat piece of work.

It is worthwhile to read it. Maybe your local library has it.

I could fax to any who provide your fax number to my email,

cacaito@bellatlantic.net

I think that if they get the data evaluated by the DSMB and the results are good they will halt the trial and it could be 3 to 6 months. Of course, I am long term in this one and my next date goal is 18 month.

The Lancet is UK and widely read in Europe and they use Meningoccemia.
Of course, one will find many more entries with N. meningitidis in a search.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext